A Phase 1-2 Study of ADCE-D01 in People With Advanced Soft Tissue Sarcoma

Full Title

A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma

Purpose

Researchers want to find the best dose of ADCE-D01 to treat soft tissue sarcoma. In this study, we treat people with soft tissue sarcoma that is inoperable (cannot be surgically removed) or metastasized (spread).

ADCE-D01 acts like a Trojan horse to kill sarcoma cells. It has two parts. One part sticks to certain proteins on cancer cells and enters the cells. Then the second part, an anti-cancer drug (poison), is released to kill them. ADCE-D01 is given intravenously (by vein). 

Contact

For more information or to see if you can join this study, please call Dr. Robert Maki’s office at 646-888-5059.